Results 71 to 80 of about 752,420 (346)

A taxonomy of cognitive phenotypes in Multiple Sclerosis: a 1-year longitudinal study

Scientific Reports
As meaningful measure of cognitive impairment (CI), cognitive phenotypes provide an avenue for symptom management and individualized rehabilitation. Since CI is highly variable in severity and progression, monitoring cognitive phenotypes over time may be
Jessica Podda, Federica Di Antonio, Andrea Tacchino, Ludovico Pedullà, Erica Grange, Mario Alberto Battaglia, Giampaolo Brichetto, Michela Ponzio   +7 more
doaj   +1 more source

Risk Factors For Multiple Sclerosis In Volyn Region (Ukraine) [PDF]

, 2016
The prevalence rate of multiple sclerosis (MS) in Volyn Region (101.0 per 100000) is the highest in Ukraine. To study MS risk factors in Volyn Region, special questionnaires were distributed among all MS patients residing in Volyn region.
Bobryk, N. (Nataliia), Sokolova, L. (Larysa)   +1 more
core   +2 more sources

SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher, Dominika Stastna, Ingrid Menkyova, Vaclav Capek, Jiri Lindner, Petra Nytrova, Jan Krasensky, Eliza Varju, Miguel D'haeseleer, Eva Kubala Havrdova, Dana Horakova, Manuela Vaneckova, Niels Bergsland   +12 more
wiley   +1 more source

Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial

Stem Cell Research & Therapy
Background Mesenchymal stem cell-neural progenitors (MSC-NPs) are a bone marrow mesenchymal stem cell (MSC)-derived ex vivo manipulated cell product with therapeutic potential in multiple sclerosis (MS).
Violaine K. Harris, James Stark, Armistead Williams, Morgan Roche, Michaela Malin, Anjali Kumar, Alyssa L. Carlson, Cara Kizilbash, Jaina Wollowitz, Caroline Andy, Linda M. Gerber, Saud A. Sadiq   +11 more
doaj   +1 more source

The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey

BMC Neurology, 2021
Background People with multiple sclerosis (MS) experience a wide range of unpredictable and variable symptoms. The symptomatology of MS has previously been reported in large sample registry studies; however, some symptoms may be underreported in ...
S. Gustavsen, A. Olsson, H. B. Søndergaard, S. R. Andresen, P. S. Sørensen, F. Sellebjerg, A. Oturai   +6 more
doaj   +1 more source

No evidence of a significant role for CTLA-4 in multiple sclerosis [PDF]

, 2006
Variation in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene plays a significant role in determining susceptibility to autoimmune thyroid disease and type 1 diabetes. Its role in multiple sclerosis is more controversial. In order to explore
Compston, A, Deans, J, Hensiek, A, Maranian, M, Roxburgh, R, Sawcer, S, Seaman, S, Yeo, T   +7 more
core  

Treating Systematic Errors in Multiple Sclerosis Data [PDF]

, 2005
Multiple sclerosis (MS) is characterized by high variability between patients and, more importantly here, within an individual over time. This makes categorization and prognosis difficult.
Confavreux, C., Daumer, Martin, Ebers, G. C., Heigenhauser, L., Kappos, L., Lederer, C., Neiß, A., Polman, C., Vukusic, S.   +8 more
core   +1 more source

Phenotyping Healthcare Use 2–3 Decades Before the First Multiple Sclerosis Demyelinating Event

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Phenotype hospital, physician, and emergency department (ED) visits by diagnoses and specialty up to 29 years pre‐multiple sclerosis (MS) onset versus a matched population without MS. Methods We identified people with MS (PwMS) using population‐based administrative data from Ontario, Canada (1991–2020).
Helen Tremlett, Karl Everett, Colleen J. Maxwell, Feng Zhu, Ayesha Asaf, Ping Li, Kyla A. McKay, Yinshan Zhao, Ruth Ann Marrie   +8 more
wiley   +1 more source

A controlled trial of natalizumab for relapsing multiple sclerosis. [PDF]

, 2003
Background: In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes.
Blumhardt, LD, Dalton, CM, Int Natalizumab Multiple Sclerosis, Khan, OA, Libonati, MA, Miller, DH, Miszkiel, KA, O'Connor, PW, Rice, GPA, Sheremata, WA, Willmer-Hulme, AJ   +10 more
core   +1 more source

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for ...
Fortunata Carbone, Alessandra Colamatteo, Teresa Micillo, Gianmarco Abbadessa, Silvia Garavelli, Clorinda Fusco, Claudia Russo, Francesco Perna, Federica Garziano, Claudia La Rocca, Maria Mottola, Giorgia Teresa Maniscalco, Simona Bonavita, Antonio Luca Spiezia, Alessia Castiello, Roberta Lanzillo, Vincenzo Brescia Morra, Claudio Procaccini, Paola de Candia, Giuseppe Matarese   +19 more
wiley   +1 more source